Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.62 |
| ▸ | CA1 | P00915 | 6/20 | 0.57 |
| ▸ | CA2 | P00918 | 6/20 | 0.57 |
| ▸ | CA4 | P22748 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204876 | 0.89 | PTGS2 (0.58) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL5201881 | 0.88 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL6883989 | 0.88 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL5205238 | 0.86 | PTGS2 (0.73) | PTGS2CA1CA2CA4KDR | |
| SCHEMBL5205884 | 0.86 | PTGS2 (0.59) | PTGS2CA1CA2CA4PTGS1 | |
| SCHEMBL5201569 | 0.86 | PTGS2 (0.62) | PTGS2CA1CA2CA4KDR | |
| SCHEMBL3352528 | 0.85 | PTGS2 (0.61) | PTGS2CA1CA2CA4KDR | |
| SCHEMBL5203437 | 0.85 | PTGS2 (0.60) | PTGS2CA1CA2CA4KDR | |
| SCHEMBL3359120 | 0.85 | PTGS2 (0.58) | PTGS2CA1CA2CA4KDR | |
| SCHEMBL5206224 | 0.84 | PTGS2 (0.60) | PTGS2CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1290842-C | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP (KR) | 2006-12-20 | — | — | CN | claimed |
| EP-1458706-A4 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CORP (KR) | 2005-06-08 | — | — | EP | claimed |
| CN-1608060-A | Diaryl 1,2, 4-triazole derivatives as highly selective cyclooxygenase-2 inhibitors | CJ CORP (KR) | 2005-04-20 | — | — | CN | claimed |
| US-20050075373-A1 | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP. (KR) | 2005-04-07 | — | — | US | claimed |
| EP-1458706-A1 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ Corp. (KR) | 2004-09-22 | — | — | EP | claimed |
| WO-2003055875-A1 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CORP. (KR) | 2003-07-10 | — | — | WO | claimed |
| EP-1458706-B1 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CORP (KR) | 2007-07-11 | — | — | EP | disclosed |
| US-7169929-B2 | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP. (KR) | 2007-01-30 | — | — | US | disclosed |
| CN-1290842-C | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP (KR) | 2006-12-20 | — | — | CN | disclosed |
| US-7135572-B2 | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP (KR) | 2006-11-14 | — | — | US | disclosed |
| US-20060009495-A1 | Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP. (KR) | 2006-01-12 | — | — | US | disclosed |
| EP-1458706-A4 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CORP (KR) | 2005-06-08 | — | — | EP | disclosed |
| CN-1608060-A | Diaryl 1,2, 4-triazole derivatives as highly selective cyclooxygenase-2 inhibitors | CJ CORP (KR) | 2005-04-20 | — | — | CN | disclosed |
| US-20050075373-A1 | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | CJ CORP. (KR) | 2005-04-07 | — | — | US | disclosed |
| EP-1458706-A1 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ Corp. (KR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055875-A1 | DIARYL 1,2,4-TRIAZOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CORP. (KR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009495-A1 | Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885CA1 1415/4885CA2 605/4885 |
| US-20050075373-A1 | Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885CA1 1611/4885CA2 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.